CUREVAC N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.31 USD | -7.97% |
|
-5.33% | -45.13% |
| Apr. 25 | Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4 | MT |
| Apr. 25 | CureVac N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 86.09M 92.39M | Sales 2025 * | 98.6M 106M | Capitalization | 483M 518M |
|---|---|---|---|---|---|
| Net income 2024 * | -194M -208M | Net income 2025 * | -110M -118M | EV / Sales 2024 * | 2.89 x |
| Net cash position 2024 * | 230M 247M | Net cash position 2025 * | 157M 168M | EV / Sales 2025 * | 3.31 x |
| P/E ratio 2024 * |
-2.28
x | P/E ratio 2025 * |
-3.24
x | Employees | 977 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.57% |
More Fundamentals
* Assessed data
More news
Latest transcript on CureVac N.V.
More press releases
More news
| 1 day | -7.97% | ||
| 1 week | -5.33% | ||
| Current month | -23.76% | ||
| 1 month | -26.67% | ||
| 3 months | -37.06% | ||
| 6 months | -58.23% | ||
| Current year | -45.13% |
1 week
2.22
2.63
1 month
2.223.19
Current year
2.224.46
1 year
2.2212.36
3 years
2.22130.48
5 years
2.22151.80
10 years
2.22151.80
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 23-03-27 | |
Pierre Kemula
DFI | Director of Finance/CFO | 50 | 16-10-31 |
Malte Greune
COO | Chief Operating Officer | 59 | 21-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Craig Tooman
BRD | Director/Board Member | 58 | 19-05-31 |
Michael Brosnan
BRD | Director/Board Member | 69 | 23-06-18 |
| Director/Board Member | 67 | 22-06-21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.74% | 17 M€ | -.--% | - | |
| 0.06% | 2 M€ | -.--% | ||
| 0.04% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 2.31 | -7.97% | 1,242,504 |
| 24-04-24 | 2.51 | -3.46% | 1,084,869 |
| 24-04-23 | 2.6 | +2.77% | 609,966 |
| 24-04-22 | 2.53 | +3.69% | 598,792 |
| 24-04-19 | 2.44 | 0.00% | 793,106 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotes
CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve peopleâs lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.
Calendar
2024-05-21
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
2.156
EUR
Average target price
13.24
EUR
Spread / Average Target
+514.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -45.13% | 517M | |
| +1.12% | 42.59B | |
| +6.77% | 40.65B | |
| +47.98% | 40.57B | |
| -11.96% | 26.77B | |
| +6.01% | 24.81B | |
| -24.92% | 18.17B | |
| -3.63% | 11.7B | |
| +27.16% | 12.05B | |
| +7.30% | 11.1B |
- Stock Market
- Equities
- CVAC Stock
